Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation

基于纳米闪烁体的 X 射线敏化剂可通过 X 射线照射实现有效的 NSCLC 治疗

基本信息

  • 批准号:
    9311376
  • 负责人:
  • 金额:
    $ 49.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-15 至 2021-01-31
  • 项目状态:
    已结题

项目摘要

Abstract Photodynamic therapy (PDT) has gained much attention as a relatively new cancer treatment modality. PDT has a favorable toxicity profile compared to radiotherapy. Meanwhile, it does not incur resistance, and can be applied to previously irradiated tissues. However, the use of PDT in the clinic has been very limited. This is largely due to its surface-weighted treatment efficacy, a result of limited penetration depth of light in tissues. Our long term objective is to develop a novel PDT derivative called X-ray induced PDT or X-PDT that can break the shallow penetration limitation. Our strategy is to use X-ray, which has great tissue penetration ability, as the energy source to trigger PDT. The key element of our technology is an integrated nanosystem, consisting of a scintillator nanoparticle core and photosensitizing drugs that match the scintillator’s emission wavelength. Upon X-ray irradiation, the nanoparticle scintillator functions as a transducer, converting X-ray photons to visible light photons. The visible photons, in turn, activate the near-by photosensitizing drugs to produce a cytotoxic species called singlet oxygen. Owing to the excellent transmittance of X-ray, X-PDT can be activated from deep tissues. Moreover, it was found that X-PDT is essentially a combination of PDT and radiotherapy. This leads to synergistic treatment outcomes, allowing X-PDT to efficiently kill cancer cells at low radiation doses, even for cancer cells that are refractory to radiotherapy. These characteristics make X-PDT an appealing treatment methodology. The present project will exploit X-PDT to treat non–small cell lung cancer (NSCLC), which is challenging or not possible for conventional PDT. NSCLC accounts for 85% of all lung cancer cases, and is diagnosed in 187,000 persons each year. Radiation, often concurrent with chemotherapy, is the standard of care for the majority of the patients. The treatment, however, may cause severe side effects such as neutropenic fever and Grade 3 esophagitis. Once recur, treatment options are limited since the radiation has been given to the maximum tolerated dose. Hence, there is an urgent need for an effective and less toxic treatment for NSCLC. It is expected that X-PDT can efficiently kill NSCLC through external radiation of relatively low doses with minimal collateral damage. Success of this project will be paradigm-shifting, breaking the shallow penetration dogma of conventional PDT and opening many new possibilities. X-PDT holds great potential in clinical translation, complementing or replacing current treatment regimens for NSCLC therapy. Although the current study is focused on NSCLC, the methodology can be easily extended to treatment of other cancer types, for instance head and neck cancer, breast cancer, and prostate cancer.
抽象的 光动力疗法(PDT)作为一种相对较新的癌症治疗方式受到了广泛关注。太平洋夏令时 与放射治疗相比,具有良好的毒性特征。同时,它不会产生阻力,并且可以 应用于先前照射过的组织。然而,PDT在临床上的应用却非常有限。这是 很大程度上是由于其表面加权治疗功效,这是光在组织中的穿透深度有限的结果。 我们的长期目标是开发一种新型 PDT 衍生物,称为 X 射线诱导 PDT 或 X-PDT,它可以 突破浅穿透限制。我们的策略是使用X射线,它具有很强的组织穿透能力, 作为触发PDT的能量来源。我们技术的关键要素是集成的纳米系统,包括 闪烁体纳米颗粒核心和与闪烁体发射波长相匹配的光敏药物。 X 射线照射后,纳米粒子闪烁体充当换能器,将 X 射线光子转换为可见光 光光子。可见光子反过来激活附近的光敏药物,产生细胞毒性 称为单线态氧的物种。由于X射线具有优异的透过率,X-PDT可以从深层激活 组织。而且,人们发现X-PDT本质上是PDT和放射治疗的结合。这导致 协同治疗结果,使 X-PDT 能够在低辐射剂量下有效杀死癌细胞,即使是 对放射治疗耐药的癌细胞。这些特征使 X-PDT 成为一种有吸引力的治疗方法 方法论。 本项目将利用 X-PDT 治疗非小细胞肺癌 (NSCLC),这是一项具有挑战性或挑战性的任务 传统 PDT 无法实现。 NSCLC 占所有肺癌病例的 85%,诊断时间为 每年 187,000 人。放射治疗通常与化疗同时进行,是患者的标准治疗方法 大多数患者。然而,这种治疗可能会引起严重的副作用,例如中性粒细胞减少性发热和 3级食管炎。一旦复发,治疗选择就会受到限制,因为放射线已经照射到患者身上。 最大耐受剂量。因此,迫切需要一种有效且毒性较小的非小细胞肺癌治疗方法。它 预计X-PDT可以通过相对低剂量的外照射,以最小的剂量有效杀灭NSCLC。 附带损害。 该项目的成功将是范式转变,打破传统的浅层渗透教条 PDT 并开启许多新的可能性。 X-PDT 在临床转化、补充或治疗方面具有巨大潜力 替代目前非小细胞肺癌治疗的治疗方案。尽管目前的研究主要集中在 NSCLC, 该方法可以轻松扩展到其他癌症类型的治疗,例如头颈癌, 乳腺癌和前列腺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jin Xie其他文献

Jin Xie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jin Xie', 18)}}的其他基金

Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiation
基于纳米闪烁体的 X 射线敏化剂可通过 X 射线照射实现有效的 NSCLC 治疗
  • 批准号:
    9899249
  • 财政年份:
    2017
  • 资助金额:
    $ 49.23万
  • 项目类别:
Nanoplatform-based combinational therapy against breast cancer
基于纳米平台的乳腺癌联合疗法
  • 批准号:
    8545104
  • 财政年份:
    2010
  • 资助金额:
    $ 49.23万
  • 项目类别:
Nanoplatform-based combinational therapy against breast cancer
基于纳米平台的乳腺癌联合疗法
  • 批准号:
    8335496
  • 财政年份:
    2010
  • 资助金额:
    $ 49.23万
  • 项目类别:
Nanoplatform-based combinational therapy against breast cancer
基于纳米平台的乳腺癌联合疗法
  • 批准号:
    8333479
  • 财政年份:
    2010
  • 资助金额:
    $ 49.23万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 49.23万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了